Brusa Livia, Petta Filomena, Farullo Giuseppe, Iacovelli Valerio, Ponzo Viviana, Iani Cesare, Stanzione Paolo, Agró Enrico Finazzi
Neurology Unit Sant'Eugenio Hospital Rome Italy.
Department of Surgery/Urology Tor Vergata University Rome Italy.
Mov Disord Clin Pract. 2017 Apr 19;4(4):586-589. doi: 10.1002/mdc3.12488. eCollection 2017 Jul-Aug.
The objective of this study was to assess the effect of rotigotine treatment on bladder function in patients with Parkinson's disease (PD) who have urinary urgency.
in total, 20 patients with PD underwent urodynamic evaluation and completed International Prostate Symptoms questionnaires in off-rotigotine condition and after 3 months of rotigotine patch monotherapy administration. In both sessions, clinical motor condition was evaluated with the Unified Parkinson Disease Rating Scale, Part III (motor part).
Rotigotine administration significantly ameliorated the first sensation of bladder filling, the neurogenic detrusor overactive contractions threshold and bladder capacity compared with the off-treatment condition. Moreover, the total score on the International Prostate Symptoms questionnaire revealed a decrease of filling (irritative) symptoms after rotigotine treatment compared with the off-treatment condition.
The positive effects of rotigotine may be due to its balanced agonism to D1 and D2 receptors and in particular to its stimulation of D1 receptors in the anterior cingulate cortex and insula, which are known as areas involved in bladder-inhibitory functions.
本研究的目的是评估罗替戈汀治疗对患有尿急的帕金森病（PD）患者膀胱功能的影响。
共有20例PD患者在停用罗替戈汀的情况下以及在接受罗替戈汀贴片单药治疗3个月后接受了尿动力学评估并完成了国际前列腺症状问卷。在这两个阶段，均使用统一帕金森病评定量表第三部分（运动部分）对临床运动状况进行评估。
与未治疗状态相比，使用罗替戈汀显著改善了膀胱充盈的首次感觉、神经源性逼尿肌过度活跃收缩阈值和膀胱容量。此外，国际前列腺症状问卷的总分显示，与未治疗状态相比，罗替戈汀治疗后充盈（刺激性）症状有所减轻。
罗替戈汀的积极作用可能归因于其对D1和D2受体的平衡激动作用，尤其是其对前扣带回皮质和脑岛中D1受体的刺激，这些区域是已知参与膀胱抑制功能的区域。
